Risk Free Fresenius Dialysis Lawsuit Funding Helps GranuFlo Victims
According to recent news, litigation against Fresenius Medical Care involving the concentrate products GranuFlo and NaturaLyte is moving forward. After the U.S. Judicial Panel on Multidistrict Litigation consolidated all federal cases into one court on March 29, 2013, plaintiffs have now filed a memo with the U.S. District Court of Massachusetts to establish an initial case management conference and establish leadership positions for those lawyers that will help coordinate the proceedings.
Currently, there are over 300 lawsuits pending against Fresenius with claims concerning GranuFlo and NaturaLyte. Plaintiffs who are waiting for their cases to resolve are likely to be pleased at the progress occurring in the MDL, but the truth is that it may still be a year or more before any of these cases actually go to trial. In the meantime, plaintiffs who have been seriously injured may be facing unexpected medical costs and lost wages. Fresenius dialysis lawsuit funding may be the ideal solution for paying off expenses without incurring additional debt.
Plaintiffs ask court to designate plaintiff management structure before conference
According to court documents, the plaintiffs’ counsel has requested the Massachusetts court designate a plaintiff management structure before the initial case management conference. They argue that doing so will help coordinate a number of preliminary administrative matters that are best addressed in advance of the conference. These may include:
- A proposed agenda for the conference
- A broad description of the claims
- The procedural status of the litigation
- A preliminary estimate of the number of cases that may become part of the MDL
- The use of medical releases and facto sheets
- Suggestions on the content of potential preservation and protective orders
- Whether the appointment of a Special Master is appropriate
“Additionally,” the plaintiffs write, “the early appointment of leadership is important to facilitate communications with the Defendants on the matters above and generally.”
The plaintiffs also propose a leadership structure, and request the court schedule a case management conference to address the appointment of leadership. Though this is an important step in litigation, it does illustrate that every step in the MDL will take time, during which GranuFlo legal loans can help plaintiffs cope with financial concerns until these cases go to trial.
Fresenius dialysis lawsuit funding: a risk free cash advance
In June 2012, the FDA issued a Class I recall for GranuFlo and NaturaLyte, two products that are used to control acid buildup in the blood during kidney dialysis treatments. A Class I recall is the agency’s most stringent as it warns physicians of the risk of serious injury, including death.
The FDA warned that inappropriate dose of these concentrates could result in high blood levels of bicarbonate, a natural alkalizing agent. High levels of bicarbonate can lead to a condition known as “metabolic alkalosis,” which in turn, increases risk of heart rhythm problems, heart attack, and sudden death.
Plaintiffs who have filed GranuFlo or NaturaLyte lawsuits may benefit from Fresenius dialysis lawsuit funding because it’s a non-recourse cash advance that is based on the estimated outcome of the case. Unlike bank loans, GranuFlo legal loans are 100 percent risk free, allowing plaintiffs to use the money they are likely to win in their case now rather than later.
More information on GranuFlo legal loans
If you or a loved one suffered a serious injury after going through dialysis with GranuFlo or NaturaLyte, and you have filed a lawsuit, you may be waiting for a year or more for a possible settlement or jury award. In the meantime, Fresenius dialysis lawsuit funding can provide you with the financial resources you need to stay afloat while awaiting the outcome of your case. At LawStreet Capital, we require no credit check and offer a hassle-free application. Call us today for more information. 1.866.FUND.662.
